Sana's Diabetes Cell Therapy Shows Durable Function at 14 Months, NEJM Publishes Follow-Up
SANA sits 43% above its 52-week low of $2.61.
Summary
Sana's hypoimmune-modified islet cells continue to produce insulin without immunosuppression at 14 months in a type 1 diabetes patient, with new data published in NEJM. C-peptide levels rebounded at month 14 after a dip, and PET-MRI confirms cell survival. The company now expects to file an IND and start a Phase 1/2 trial for SC451 as early as this year, accelerating the path to a potential functional cure. This follows a going-concern warning and recent ATM equity raises, making the clinical progress critical for the company's outlook. The NEJM publication adds significant validation to the platform.
At the time of this announcement, SANA was trading at $3.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.61 to $6.55. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.